Further research specifically designed to assess sexual health outcomes in semaglutide users would provide valuable clinical guidance
The difference between stopping and continuing treatment is stark: discontinuation typically results in 5070% weight regain within 12 months, while continuous therapy preserves results
Liver Disease: Generally safe when used as directed
More recent research has explored AOD9604 for other potential applications beyond obesity, including osteoarthritis treatment based on observations of cartilage regeneration properties in preclinical models, though clinical validation of these additional indications is limited
Both medications offer effective solutions for individuals struggling with weight management, with Tirzepatide showing slightly more promise in clinical trials
In studies of people without diabetes, less than 1% of participants receiving Ozempic for weight management experienced hypoglycemia